Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant

被引：20

作者：

Bewersdorf, Jan Philipp ^{[1
]}

Derkach, Andriy ^{[2
]}

Gowda, Lohith ^{[1
]}

Menghrajani, Kamal ^{[3
,4
]}

DeWolf, Susan ^{[3
]}

Ruiz, Josel D. ^{[5
]}

Ponce, Doris M. ^{[4
,5
]}

Shaffer, Brian C. ^{[4
,5
]}

Tamari, Roni ^{[4
,5
]}

Young, James W. ^{[4
,5
,6
]}

Jakubowski, Ann A. ^{[4
,5
]}

Gyurkocza, Boglarka ^{[4
,5
]}

Chan, Alexander ^{[7
]}

Xiao, Wenbin ^{[7
]}

Glass, Jacob ^{[3
,4
]}

King, Amber C. ^{[8
]}

Cai, Sheng F. ^{[3
,4
]}

Daniyan, Anthony ^{[3
,4
]}

Famulare, Christopher ^{[3
]}

Cuello, Bernadette M. ^{[3
]}

Podoltsev, Nikolai A. ^{[1
]}

Roshal, Mikhail ^{[7
]}

Giralt, Sergio ^{[4
,5
]}

Perales, Miguel-Angel ^{[4
,5
]}

Seropian, Stuart ^{[1
]}

Cho, Christina ^{[4
,5
]}

Zeidan, Amer M. ^{[1
]}

Prebet, Thomas ^{[1
]}

Stein, Eytan M. ^{[3
,4
]}

Tallman, Martin S. ^{[3
,4
]}

Goldberg, Aaron D. ^{[3
,4
]}

Stahl, Maximilian ^{[3
,4
]}

机构：

[1] Yale Univ, Sch Med, Dept Internal Med, Sect Hematol, New Haven, CT 06510 USA

[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA

[3] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY 10065 USA

[4] Weill Cornell Med Coll, New York, NY USA

[5] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplantat Serv, New York, NY 10065 USA

[6] Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA

[7] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA

[8] Mem Sloan Kettering Canc Ctr, Dept Pharm, New York, NY 10065 USA

来源：

LEUKEMIA & LYMPHOMA | 2021年 / 62卷 / 14期

基金：

美国国家卫生研究院;

关键词：

Acute myeloid leukemia; AML; MDS; venetoclax; transplant; RELAPSE;

D O I：

10.1080/10428194.2021.1966788

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The role of allogeneic hematopoietic cell transplant (allo-HCT) as consolidation after initial venetoclax therapy and the efficacy of venetoclax salvage therapy for relapse after allo-HCT in patients with acute myeloid leukemia (AML) are unclear. We conducted a retrospective study of patients with AML or myelodysplastic syndrome (MDS) who received venetoclax either before or after allo-HCT at Memorial Sloan Kettering Cancer Center and Yale University from 11 August 2016 to 16 November 2020. Among 39 heavily pretreated patients who received venetoclax before allo-HCT, median OS from allo-HCT was not reached after a median follow up of 12.5 months resulting in a 12-month OS estimate of 79.0%. In 37 patients who had received venetoclax-based combinations as salvage therapy after allo-HCT, the overall response rate was 32% with a median OS of 4.7 months (12-month OS estimate: 43.4%). Four patients underwent a second allo-HCT following venetoclax-based salvage therapy suggesting it as a potential salvage treatment option.

引用

页码：3394 / 3401

页数：8

共 50 条

[41] Comparable outcomes for TBI-based versus treosulfan based conditioning prior to allogeneic hematopoietic stem cell transplantation in AML and MDS patients
Berning, Philipp
Kolloch, Lina
Reicherts, Christian
Call, Simon
Marx, Julia
Floeth, Matthias
Esseling, Eva
Ronnacker, Julian
Albring, Joern
Schliemann, Christoph
Lenz, Georg
Stelljes, Matthias
BONE MARROW TRANSPLANTATION, 2024, 59 (08) : 1097 - 1106
[42] Effect of comorbidities on allogeneic hematopoietic stem cell transplant outcomes in AML/MDS patients in first complete remission
Shahjahan, M
Alamo, J
de Lima, M
Khouri, I
Gajewski, J
Andersson, B
Champlin, R
Giralt, SM
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2004, 10 (02) : 12 - 13
[43] Allogeneic stem cell transplantation after chemotherapy and dose reduced-intensity conditioning for high-risk AML and MDS
Schleuning, M
Schmid, C
Ledderose, G
Tischer, J
Weisser, M
Humann, M
Kolb, HJ
BONE MARROW TRANSPLANTATION, 2003, 31 : S29 - S30
[44] Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia
Kim, Haesook T.
Shaughnessy, Conner J.
Rai, Sharmila C.
Reynolds, Carol
Ho, Vincent T.
Cutler, Corey
Koreth, John
Gooptu, Mahasweta
Romee, Rizwan
Nikiforow, Sarah
Armand, Philippe
Alyea, Edwin P.
Antin, Joseph H.
Wu, Catherine J.
Soiffer, Robert J.
Ritz, Jerome
Brown, Jennifer R.
BLOOD ADVANCES, 2020, 4 (17) : 4113 - 4123
[45] Favorable results of prophylactic donor lymphocyte transfusions following allogeneic stem cell transplantation after reduced intensity conditioning for high-risk AML and MDS
Schleuning, M
Schmid, C
Ledderose, G
Tischer, J
Baurmann, H
Schwerdtfeger, R
Kolb, HJ
EXPERIMENTAL HEMATOLOGY, 2005, 33 (07) : 47 - 47
[46] Treosulfan-Based Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Patients with Myelodysplastic Syndrome (MDS): Promising Survival Outcome Including Patients with High-Risk Disease
Floeth, Matthias
Beckmann, Elena
Reicherts, Christian
Marx, Julia
Call, Simon
Shaforostova, Inna
Esseling, Eva
Albring, Jorn
Mikesch, Jan-Henrik
Schliemann, Christoph
Lenz, Georg
Stelljes, Matthias
BLOOD, 2022, 140 : 7587 - 7588
[47] PROPHYLAXIS OF INVASIVE FUNGAL INFECTION WITH VORICONAZOLE IN HIGH-RISK ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
Gutierrez, L.
Martinez-Mugica, C.
Gonzalez, A. J.
Solano, J.
Duenas, V.
Palomo, P.
Gonzalez, A. P.
Gonzalez, S.
Rayon, C.
Vallejo, C.
BONE MARROW TRANSPLANTATION, 2014, 49 : S467 - S467
[48] Allogeneic stem cell transplantation (AlloSCT) for patients (pts) with acute leukemia following venetoclax-based therapy.
Mukherjee, Akash
Milton, Denai R.
Jabbour, Elias
Konopleva, Marina
Dinardo, Courtney Denton
Gulbis, Alison
Ravandi, Farhad
Daver, Naval Guastad
Kadia, Tapan M.
Oran, Betul
Popat, Uday R.
Ciurea, Stefan O.
Im, Jin
Kebriaei, Partow
Mehta, Rohtesh S.
Kantarjian, Hagop M.
Champlin, Richard E.
Khouri, Issa F.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[49] Preconditioning intervention prior to allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia
Tachibana, Takayoshi
Izumi, Akihiko
Arai, Shota
Takeda, Takaaki
Hirose, Natsuki
Tamai, Yotaro
Sato, Shuku
Hashimoto, Chizuko
Fujimaki, Katsumichi
Ishii, Ryuji
Sakai, Hirotaka
Yamazaki, Etsuko
Inoue, Yasuyuki
Tanaka, Masatsugu
Nakajima, Hideaki
EXPERIMENTAL HEMATOLOGY, 2025, 144
[50] Clostridium Difficile infections in patients with AML or MDS undergoing allogeneic hematopoietic stem cell transplantation identify high risk for adverse outcome
Amberge, Simon
Kramer, Michael
Schroettner, Percy
Heidrich, Katharina
Schmelz, Renate
Middeke, Jan M.
Gunzer, Florian
Hampe, Jochen
Schetelig, Johannes
Bornhaeuser, Martin
Stoelzel, Friedrich
BONE MARROW TRANSPLANTATION, 2020, 55 (02) : 367 - 375

← 1 2 3 4 5 →